TROPION-Lung01 Study Design and Baseline demographics
Best change from baseline
in target lesion size (%)
BEGONIA Arm 7: Dato-DXd + Durvalumab
Antitumour Responses in 1L a/mTNBC
100
Confirmed ORR was 79% (49/62; 95% CI, 66.8ā88.3) with 6 CR and 43 PR
ā Antitumour responses were observed regardless of PD-L1 expression level as
assessed by 2 separate PD-L1 assays and scoring methods
50-
0
-50-
H High
#
PD-L1
expression
L Low
-100
U Unknown/Missing
SP263 PD-L1 TAP
10% cutoff
LLLHLLLLHLLHH
22C3 PD-L1 CPS 10 cutoff
LL
LLHLLLLHLLHHLLLLLU
Progressive disease
Stable disease
LLL
HLLLLLLL
HLHLLLLL
Not evaluable
Partial response
.L LHLLL
LLLHLHLL
Complete response
Dotted lines indicate thresholds for partial response (-30%) and progressive disease (20%). PD-L1 expression was assessed by 1) immunohistochemistry using the VENTANA PD-L1 (SP263) Assay with expression defined as the percentage of the tumour area populated by tumour or immune cells with
membranous staining (TAP), or 2) immunohistochemistry using the 2203 antibody with expression defined as the number of PD-L1-staining tumour cells, lymphocytes, and macrophages, divided by the total number of viable tumour cells, multiplied by 100 (CPS). *Ifthe best percentage change from
baseline of target lesions cannot be calculated due to progression, withdrawal, or death, the value is imputed at +20%.***Patients with PD as best overall response. *Unconfirmed response.
1L, first line; a/m TNBC, advanced/metastatic triple-negative breast cancer; CI, confidence interval; CPS, combined positive score; CR, complete response; Dato-DXd, datopotamab deruxtecan; ORR, objective response rate; PD-L1, programmed cell death ligand-1; PR, parial response;
TAP, tumour area positivity.
Data cutoff. 02 Feb 2023
Daiichi-Sankyo
39View entire presentation